**Supplementary Table 7.** Baseline Characteristics of Patients with a Confirmed Diagnosis of Ulcerative Colitis by Second Line Treatment

| Characteristic | Adalimumab (n = 86) | Infliximab (n = 129) | Golimumab (n = 114) | Vedolizumab (n = 125) | Ustekinumab (n = 124) | Tofacitinib (n = 106) | Filgotinib (n = 10) |
|---|---|---|---|---|---|---|---|
| Sex | | | | | | | |
| Male | 51 (59.3) | 96 (74.4) | 63 (55.3) | 85 (68.0) | 86 (69.4) | 68 (64.2) | 6 (60.0) |
| Female | 35 (40.7) | 33 (25.6) | 51 (44.7) | 40 (32.0) | 38 (30.6) | 38 (35.8) | 4 (40.0) |
| Age at commencement of second line (yr) | | | | | | | |
| Mean ± SD | 37.6 ± 13.0 | 39.7 ± 14.6 | 41.5 ± 12.8 | 40.9 ± 13.3 | 39.8 ± 13.9 | 38.6 ± 12.5 | 37.4 ± 11.6 |
| Median (IQR) | 38 (27–46) | 39 (27–52) | 42 (31–51) | 43 (30–52) | 41 (27–51) | 39 (27–49) | 42 (27–46) |
| Charlson Comorbidity Index | | | | | | | |
| Mean ± SD | 0.74 ± 1.00 | 0.99 ± 1.20 | 0.85 ± 0.90 | 1.17 ± 1.70 | 0.96 ± 1.50 | 0.91 ± 1.30 | 0.70 ± 0.90 |
| Median (IQR) | 0 (0–1) | 1 (0–1) | 1 (0–1) | 1 (0–2) | 1 (0–1) | 0 (0–2) | 0.5 (0–1) |
| 0 | 46 (53.5) | 53 (41.1) | 51 (44.7) | 56 (44.8) | 57 (46.0) | 55 (51.9) | 5 (50.0) |
| 1–2 | 35 (40.7) | 63 (48.8) | 58 (50.9) | 55 (44.0) | 55 (44.4) | 41 (38.7) | 4 (40.0) |
| 3–5 | 5 (5.8) | 11 (8.5) | 5 (4.4) | 10 (8.0) | 10 (8.1) | 9 (8.5) | 1 (10.0) |
| > 5 | 0 | 2 (1.6) | 0 | 4 (3.2) | 2 (1.6) | 1 (0.9) | 0 |
| Hospitalizations within 6 mo prior to second line | | | | | | | |
| Yes | 15 (17.4) | 65 (50.4) | 28 (24.6) | 25 (20.0) | 24 (19.4) | 29 (27.4) | 0 |
| No | 71 (82.6) | 64 (49.6) | 86 (75.4) | 100 (80.0) | 100 (80.6) | 77 (72.6) | 10 (100.0) |
| Time from first- to second line (day) | | | | | | | |
| Mean ± SD | 467.3 ± 404.6 | 240.8 ± 322.8 | 446.4 ± 487.4 | 473.4 ± 468.3 | 537.6 ± 646.5 | 385.8 ± 465.2 | 733.0 ± 324.9 |
| Median (IQR) | 317 (196–672) | 143 (72–284) | 267 (154–576) | 308 (126–665) | 326 (145–608) | 180 (84–497) | 714 (413–1,074) |

Values are presented as number (%) unless otherwise indicated.
SD, standard deviation; IQR, interquartile range.